MBT-0206

paclitaxel encapsulated in cationic lipid complexes, impairs functional tumor vascular properties

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2006 - "Immunohistological analysis confirmed a significant reduction of microvessel density in MBT-0206 treated tumors. " 01/01/2006 - "Twenty-four hours after three intravenous applications of MBT-0206, tumors of treated animals demonstrated a significant decrease of intratumoral blood volume and an increase of vascular permeability in comparison to size-matched control tumors. " 01/01/2006 - "As noninvasive imaging techniques are of critical importance for optimizing antivascular cancer treatment in the clinic, we have evaluated the antivascular effects of MBT-0206 in the A-MEL-3 solid tumor model using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). " 01/01/2006 - "In conclusion, antivascular tumor therapy with MBT-0206 significantly impairs functional tumor microcirculation. " 05/20/2004 - "Tumor growth was significantly retarded after treatment with MBT-0206 compared to the treatment with paclitaxel. "
2.	Body Weight (Weight, Body) 05/20/2004 - "Tumors were treated with intravenous infusion of MBT-0206 (20 mM) resulting in an effective paclitaxel dose of 5 mg/kg body weight (b.w.). "

1.	Paclitaxel (Taxol)